Lipid Rafts and Fas/CD95 Signaling in Cancer Chemotherapy

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 3, 2011, Pages 274-283

  Gajate, Consuelo ^a,b   Mollinedo, Faustino ^a  

^a Salamanca Spain   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Alkyl lysophospholipid analogue; Apoptotic signaling; Cancer therapy; Edelfosine; Ether phospholipid; Fas CD95; Lipid rafts; Membrane microdomains

Indexed keywords

ALKYLLYSOPHOSPHOLIPID; CERAMIDE; CHOLESTEROL; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR; DEHYDRODIDEMNIN B; EDELFOSINE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; LIPOSOME; PERIFOSINE; PROCASPASE 8; PROTEIN BID; RESVERATROL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CELL MEMBRANE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG BINDING; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RELEASE; DRUG TARGETING; HEMOLYSIS; HUMAN; IN VIVO STUDY; LIPID RAFT; LIVER TOXICITY; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MEMBRANE MICRODOMAINS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 80052341675     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211796957766     Document Type: Article

References (129)

1. Gajate C, Mollinedo F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET- 18-OCH3 (edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab 2002; 3: 491-525.
2. Mollinedo F, Gajate C, Martin-Santamaria S, Gago F. ET-18-OCH3 (edelfosine): A selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem 2004; 11: 3163-3184.
3. Gajate C, Fonteriz RI, Cabaner C, Alvarez-Noves G, Alvarez- Rodriguez Y, Modolell M, et al. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipidinduced apoptosis. Int J Cancer 2000; 85: 674-62.
4. Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 2001; 98: 3860-3863.
5. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 31-39.
6. Munro S. Lipid rafts: Elusive or illusive? Cell 2003; 115: 377-388.
7. Hueber AO, Bernard AM, Herincs Z, Couzinet A, He HT. An essential role for membrane rafts in the initiation of Fas/CD95- triggered cell death in mouse thymocytes. EMBO Rep 2002; 3: 190-196.
8. Scheel-Toellner D, Wang K, Singh R, Majeed S, Raza K, Curnow SJ, et al. The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem Biophys Res Commun 2002; 297: 876-879.
9. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH et al. Cytotoxicity-dependent APO-1 (Fas/CD95)- associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J 1995; 14: 5579-5588.
10. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305-1308.
11. Salvesen GS, Dixit VM. Caspase activation: The inducedproximity model. Proc Natl Acad Sci USA 1999; 96: 10964-10967.
12. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
13. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490.
14. Wang L, Yang JK, Kabaleeswaran V, Rice AJ, Cruz AC, Park AY, et al. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat Struct Mol Biol 2010; 17: 1324-1329.
15. Esposito D, Sankar A, Morgner N, Robinson CV, Rittinger K, Driscoll PC. Solution NMR investigation of the CD95/FADD homotypic death domain complex suggests lack of engagement of the CD95 C terminus. Structure 2010; 18: 1378-1390.
16. Hymowitz SG, Dixit VM. Unleashing cell death: The Fas-FADD complex. Nat Struct Mol Biol 2010; 17: 1289-1290.
17. Miyaji M, Jin ZX, Yamaoka S, Amakawa R, Fukuhara S, Sato SB, et al. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med 2005; 202: 249-259.
18. Scheel-Toellner D, Wang K, Assi LK, Webb PR, Craddock RM, Salmon M et al. Clustering of death receptors in lipid rafts initiates neutrophil spontaneous apoptosis. Biochem Soc Trans 2004; 32: 679-681.
19. Grassme H, Cremesti A, Kolesnick R, Gulbins E. Ceramidemediated clustering is required for CD95-DISC formation. Oncogene 2003; 22: 5457-5470.
20. Prinetti A, Chigorno V, Prioni S, Loberto N, Marano N, Tettamanti G, et al. Changes in the lipid turnover, composition, and organization, as sphingolipid-enriched membrane domains, in rat cerebellar granule cells developing in vitro. J Biol Chem 2001; 276: 21136-21145.
21. Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 2008; 1785: 182-206.
22. Patra SK, Rizzi F, Silva A, Rugina DO, Bettuzzi S. Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): Specificity and interaction with membrane lipid rafts. J Physiol Pharmacol 2008; 59 Suppl 9: 217-235.
23. Chakrabandhu K, Herincs Z, Huault S, Dost B, Peng L, Conchonaud F, et al. Palmitoylation is required for efficient Fas cell death signaling. Embo J 2007; 26: 209-220.
24. Lee KH, Feig C, Tchikov V, Schickel R, Hallas C, Schutze S, et al. The role of receptor internalization in CD95 signaling. Embo J 2006; 25: 1009-1023.
25. Gajate C, Del Canto-Janez E, Acuna AU, Amat-Guerri F, Geijo E, Santos-Beneit AM, et al. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med 2004; 200: 353-365.
26. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109: 711-719.
27. Gajate C, Gonzalez-Camacho F, Mollinedo F. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS ONE 2009; 4: e5044.
28. Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O, et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 2004;64:3593-3598.
29. Delmas D, Rebe C, Lacour S, Filomenko R, Athias A, Gambert P, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 2003; 278: 41482-41490.
30. Reis-Sobreiro M, Gajate C, Mollinedo F. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene 2009; 28: 3221-3234.
31. Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem 2005; 280: 11641-11647.
32. Stel AJ, Ten Cate B, Jacobs S, Kok JW, Spierings DC, Dondorff M, et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol 2007; 178: 2287-2295.
33. Xu ZX, Ding T, Haridas V, Connolly F, Gutterman JU. Avicin D, a plant triterpenoid, induces cell apoptosis by recruitment of Fas and downstream signaling molecules into lipid rafts. PLoS One 2009; 4: e8532.
34. Gajate C, Gonzalez-Camacho F, Mollinedo F. Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem Biophys Res Commun 2009; 380: 780-784.
35. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH. The role of c- Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 1996; 271: 31929-31936.
36. Gajate C, Santos-Beneit A, Modolell M, Mollinedo F. Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methylrac-glycero-3-phosphocholine. Mol Pharmacol 1998; 53: 602-612.
37. Gajate C, An F, Mollinedo F. Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95-and mitochondrial-mediated mechanism. Clin Cancer Res 2003; 9: 1535-1545.
38. Delmas D, Rebe C, Micheau O, Athias A, Gambert P, Grazide S, et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004; 23: 8979-8986.
39. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241-243.
40. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-620.
41. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599-609.
42. Mollinedo F, Gajate C. Lipid rafts, death receptors and CASMERs: New insights for cancer therapy. Future Oncol 2010; 6: 491-494.
43. Mollinedo F, Gajate C. Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy. Future Oncol 2010; 6: 811-821.
44. Mollinedo F, Gajate C. Fas/CD95 death receptor and lipid rafts: New targets for apoptosis-directed cancer therapy. Drug Resist Updat 2006; 9: 51-73.
45. Zaremberg V, Gajate C, Cacharro LM, Mollinedo F, McMaster CR. Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition. J Biol Chem 2005; 280: 38047-38058.
46. van der Luit AH, Budde M, Ruurs P, Verheij M, van Blitterswijk WJ. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem 2002; 277: 39541-39547.
47. van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M, et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther 2007; 6: 2337-2345.
48. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, Campanero MA, et al. Lipid rafttargeted therapy in multiple myeloma. Oncogene 2010; 29: 3748-3757.
49. Busto JV, del Canto-Jañez E, Goñi FM, Mollinedo F, Alonso A. Combination of the anti-tumour cell ether lipid edelfosine with sterols abolishes haemolytic side effects of the drug. J Chem Biol 2008; 1: 89-94.
50. Ausili A, Torrecillas A, Aranda FJ, Mollinedo F, Gajate C, Corbalan-Garcia S, et al. Edelfosine is incorporated into rafts and alters their organization. J Phys Chem B 2008; 112: 11643-11654.
51. Garcia A, Cayla X, Fleischer A, Guergnon J, Alvarez-Franco Canas F, Rebollo MP, et al. Rafts: A simple way to control apoptosis by subcellular redistribution. Biochimie 2003; 85: 727-731.
52. Hakomori S. Role of gangliosides in tumor progression. Prog Brain Res 1994; 101: 241-250.
53. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996; 56: 5309-5318.
54. Cazet A, Groux-Degroote S, Teylaert B, Kwon KM, Lehoux S, Slomianny C, et al. GD3 synthase overexpression enhances proliferation and migration of MDA-MB-231 breast cancer cells. Biol Chem 2009; 390: 601-609.
55. Hatano K, Miyamoto Y, Nonomura N, Kaneda Y. Expression of gangliosides, GD1a and sialyl paragloboside, is regulated by NFkappaB-dependent transcriptional control of alpha2,3-sialyltransferase I, II and VI in human castration-resistant prostate cancer cells. Int J Cancer (In Press).
56. Hac-Wydro K, Dynarowicz-Latka P. Searching for the role of membrane sphingolipids in selectivity of antitumor ether lipidedelfosine. Colloids Surf B Biointerfaces 2010; 81: 492-497.
57. Hac-Wydro K, Dynarowicz-Latka P. The relationship between the concentration of ganglioside GM1 and antitumor activity of edelfosine--the Langmuir monolayer study. Colloids Surf B Biointerfaces 2010; 81: 385-388.
58. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, de Frias M, et al. In vitro and in vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 2010; 16: 2046-2054.
59. de Mendoza AE, Campanero MA, de la Iglesia-Vicente J, Gajate C, Mollinedo F, Blanco-Prieto MJ. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin Cancer Res 2009; 15: 858-864.
60. Mollinedo F, Gajate C, Morales AI, del Canto-Janez E, Justies N, Collia F, et al. Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J Pharmacol Exp Ther 2009; 329: 439-449.
61. Zerp SF, Vink SR, Ruiter GA, Koolwijk P, Peters E, van der Luit AH, et al. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: Antiangiogenic properties of a new class of antitumor agents. Anticancer Drugs 2008; 19: 65-75.
62. Dessi S, Batetta B, Pulisci D, Spano O, Anchisi C, Tessitore L, et al. Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer. Cancer 1994; 73: 253-258.
63. Kolanjiappan K, Ramachandran CR, Manoharan S. Biochemical changes in tumor tissues of oral cancer patients. Clin Biochem 2003; 36: 61-65.
64. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2004; 91: 54-69.
65. Tosi MR, Tugnoli V. Cholesteryl esters in malignancy. Clin Chim Acta 2005; 359: 27-45.
66. Li YC, Park MJ, Ye SK, Kim CW, Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 2006; 168: 1107-1118.
67. Mollinedo F. Antitumor ether lipids: Proapoptotic agents with multiple therapeutic indications. Expert Opin Ther Patents 2007; 17: 385-405.
68. Mollinedo F, Martinez-Dalmau R, Modolell M. Early and selective induction of apoptosis in human leukemic cells by the alkyllysophospholipid ET-18-OCH3. Biochem Biophys Res Commun 1993; 192: 603-609.
69. Mollinedo F, Fernandez-Luna JL, Gajate C, Martin-Martin B, Benito A, Martinez-Dalmau R, et al. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): Molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-XL. Cancer Res 1997; 57: 1320-1328.
70. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochim Biophys Acta 2004; 1697: 3-16.
71. Scheid MP, Woodgett JR. PKB/AKT: Functional insights from genetic models. Nat Rev Mol Cell Biol 2001; 2: 760-768.
72. Scheid MP, Marignani PA, Woodgett JR. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 2002; 22: 6247-6260.
73. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003; 546: 108-112.
74. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterolrich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 2002; 62: 2227-2231.
75. Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K, et al. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res 2007; 67: 6238-6246.
76. Hill MM, Feng J, Hemmings BA. Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol 2002; 12: 1251-1255.
77. Lee KY, D'Acquisto F, Hayden MS, Shim JH, Ghosh S. PDK1 nucleates T cell receptor-induced signaling complex for NFkappaB activation. Science 2005; 308: 114-118.
78. Lasserre R, Guo XJ, Conchonaud F, Hamon Y, Hawchar O, Bernard AM, et al. Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol 2008; 4: 538-547.
79. Calay D, Vind-Kezunovic D, Frankart A, Lambert S, Poumay Y, Gniadecki R. Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes. J Invest Dermatol 2010; 130: 1136-1145.
80. Remijsen Q, vanden Berghe T, Parthoens E, Asselbergh B, Vandenabeele P, Willems J. Inhibition of spontaneous neutrophil apoptosis by parabutoporin acts independently of NADPH oxidase inhibition but by lipid raft-dependent stimulation of Akt. J Leukoc Biol 2009; 85: 497-507.
81. Lee SH, Koo KH, Park JW, Kim HJ, Ye SK, Park JB, et al. HIF-1 is induced via EGFR activation and mediates resistance to anoikislike cell death under lipid rafts/caveolae-disrupting stress. Carcinogenesis 2009; 30: 1997-2004.
82. Park EK, Park MJ, Lee SH, Li YC, Kim J, Lee JS, et al. Cholesterol depletion induces anoikis-like apoptosis via FAK downregulation and caveolae internalization. J Pathol 2009; 218: 337-349.
83. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005; 115: 959-968.
84. Solomon KR, Pelton K, Boucher K, Joo J, Tully C, Zurakowski D, et al. Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol 2009; 174: 1017-1026.
85. Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS, Hong SJ. Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate 2007; 67: 1061-1069.
86. Ruiter GA, Zerp SF, Bartelink H, Van Blitterswijk WJ, Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003; 14: 167-173.
87. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053-4062.
88. Matzke A, Massing U, Krug HF. Killing tumour cells by alkylphosphocholines: Evidence for involvement of CD95. Eur J Cell Biol 2001; 80: 1-10.
89. Nieto-Miguel T, Gajate C, Gonzalez-Camacho F, Mollinedo F. Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy. Oncogene 2008; 27: 1779-1787.
90. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-772.
91. Remacle-Bonnet M, Garrouste F, Baillat G, Andre F, Marvaldi J, Pommier G. Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am J Pathol 2005; 167: 761-773.
92. Kay, H. Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods. WO2008144616 (2008).
93. Braxmeier, T., Friedrichson, T., Frohner, W., Jennings, G., Schlechtingen, G., Schroeder, C., Knolker, H.-J., Simons, K., Zerial, M., Kurzchalia, T. Sphingolipid-derived phamaceutical compositions. US2008090913 (2008).
94. Sun, H., Ghosh, P., Kim, Y. Methods of treating cancer by interfering with IGF-I receptor signaling. WO2008112297 (2008).
95. Kim, T.-W., Dipaolo, G., Kang, M.S., Berman, D.E., Mcintire, L.B.J. Phosphoinositide modulation for the treatment of neurodegenerative diseases. US2010035811 (2010).
96. Khan, A.A. In vitro model for neuronal death. US20080227201 (2008).
97. Ayllon V, Fleischer A, Cayla X, Garcia A, Rebollo A. Segregation of Bad from lipid rafts is implicated in the induction of apoptosis. J Immunol 2002; 168: 3387-3393.
98. Garcia, A., Cayla, X., Rebollo, A., Ayllon, V., Fleischer, A. Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents. US2007184435 (2007).
99. Khan, S. Synthetic lipid rafts and methods of use. WO2007112107 (2007).
100. Engebraaten O, Bjerkvig R, Berens ME. Effect of alkyllysophospholipid on glioblastoma cell invasion into fetal rat brain tissue in vitro. Cancer Res 1991; 51: 1713-1719.
101. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate 2006; 66: 32-48.
102. Zhang Q, Furukawa K, Chen HH, Sakakibara T, Urano T. Metastatic potential of mouse Lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix metalloprotease-9 localization in lipid rafts. J Biol Chem 2006; 281: 18145-1855.
103. Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 2008; 6: 446-457.
104. Xu C, Zhang YH, Thangavel M, Richardson MM, Liu L, Zhou B, et al. CD82 endocytosis and cholesterol-dependent reorganization of tetraspanin webs and lipid rafts. Faseb J 2009; 23: 3273-3288.
105. Yamaguchi H, Takeo Y, Yoshida S, Kouchi Z, Nakamura Y, Fukami K. Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. Cancer Res 2009; 69: 8594-8602.
106. Duhon D, Bigelow RL, Coleman DT, Steffan JJ, Yu C, Langston W, et al. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol Carcinog 2010; 49: 739-749.
107. Storme GA, Berdel WE, van Blitterswijk WJ, Bruyneel EA, De Bruyne GK, Mareel MM. Antiinvasive effect of racemic 1-Ooctadecyl- 2-O-methylglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro. Cancer Res 1985; 45: 351-357.
108. van Blitterswijk WJ, Hilkmann H, Storme GA. Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion. Lipids 1987; 22: 820-823.
109. Mareel M, Bracke M, Bruyneel E, van Larebeke N, de Mets M. Invasion and metastasis control: Implications for increased therapeutic index of antitumor drugs. Cancer Treat Rev 1990; 17: 335-338.
110. Schallier DC, Bruyneel EA, Storme GA, Hilgard P, Mareel MM. Antiinvasive activity of hexadecylphosphocholine in vitro. Anticancer Res 1991; 11: 1285-1292.
111. Schallier DC, Bruyneel EA, Storme GA, Mareel MM. Role of the host tissue in the anti-invasive activity of the alkyllysophospholipid, ET-18-OCH3, in vitro. Clin Exp Metastasis 1991; 9: 579-591.
112. van Larebeke NA, Bruyneel EA, Mareel MM. An anti-invasive concentration of the alkyl-lysophospholipid ET-18-OCH3 enhances the motility of embryonal chick heart cells cultured on solid substrate. Clin Exp Metastasis 1994; 12: 255-261.
113. Leroy A, de Bruyne GK, Oomen LC, Mareel MM. Alkylphospholipids reversibly open epithelial tight junctions. Anticancer Res 2003; 23: 27-32.
114. Nagler, A. Edelfosin for the treatment of brain tumors. US6514519 (2003).
115. Berdel WE, Fink U, Rastetter J. Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3. Lipids 1987; 22: 967-969.
116. Estella-Hermoso de Mendoza A, Campanero MA, de la Iglesia-Vicente J, Gajate C, Mollinedo F, Blanco-Prieto MJ. Antitumor alkyl ether lipid edelfosine: Tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin Cancer Res 2009; 15: 858-864.
117. Kelley EE, Modest EJ, Burns CP. Unidirectional membrane uptake of the ether lipid antineoplastic agent edelfosine by L1210 cells. Biochem Pharmacol 1993; 45: 2435-2439.
118. Ahmad I, Filep JJ, Franklin JC, Janoff AS, Masters GR, Pattassery J, et al. Enhanced therapeutic effects of liposome-associated 1-Ooctadecyl- 2-O- methyl-sn-glycero-3-phosphocholine. Cancer Res 1997; 57: 1915-1921.
119. Mayhew, E., Janoff, A.S., Ahmad, I., Bhatia, S.K. Etherlipidcontaining multiple lipid liposomes. US6180137 (2001).
120. Israelachvili JN, Marcelja S, Horn RG. Physical principles of membrane organization. Q Rev Biophys 1980; 13: 121-200.
121. Hanson PK, Malone L, Birchmore JL, Nichols JW. Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. J Biol Chem 2003; 278: 36041-36050.
122. Weichert, J., Longino, M. Virtual colonoscopy with radiolabeled phospholipid ether analogs. US20070098633 (2007).
123. Bussat, P., Cherkaoui, S., Fan, H., Lamy, B., Nanjappan, P., Pillai, R., Pochon, S., Song, B., Swenson, R.E. Targeting vectorphospholipids conjugates. US20090131636 (2009).
124. Braxmeier, T., Friedrichson, T., Jennings, G. Means and methods for the treatment and prevention of allergic diseases. US2009018105 (2009).
125. Gajate, C., Camprubi, J. Use of etherlysophospholipids as anti-inflammatory agents. US6583127 (2003).
126. Birch, R., Hendersen, I.C. Co-administration of perifosine with chemotherapeutics. WO2006081452 (2006).
127. Scheuring, U., Bernard, I. Combination therapy comprising a diaryl urea compound and a PI3, Akt kinase or mTOR inhibitors (rapamycins) for cancer treatment. WO2006125540 (2006).
128. Dimberg LY, Dimberg AI, Ivarsson K, Stromberg T, Osterborg A, Nilsson K, et al. Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood 2005; 106: 1346-1354.
129. Gajate C, Santos-Beneit AM, Macho A, Lazaro M, Hernandez-de Rojas A, Modolell M, et al. Involvement of mitochondria and caspase-3 in ET-18-OCH3-induced apoptosis of human leukemic cells. Int J Cancer 2000; 86: 208-218.